Silverberg Bernstein Capital Management’s Apyx Medical APYX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.5M Sell
1,022,239
-17,402
-2% -$60.8K 1.18% 21
2026
Q2
$4.67M Sell
1,039,641
-1,429
-0.1% -$5.67K 1.79% 15
2026
Q1
$3.84M Buy
1,041,070
+8,067
+0.8% +$30.1K 2.12% 12
2025
Q4
$3.62M Buy
1,033,003
+46,500
+5% +$162K 2.09% 14
2025
Q3
$2.11M Buy
986,503
+89,767
+10% +$190K 1.28% 21
2025
Q2
$2.02M Buy
896,736
+250,167
+39% +$352K 1.38% 19
2025
Q1
$886K Buy
646,569
+75,337
+13% +$104K 0.82% 32
2024
Q4
$903K Sell
571,232
-1,400
-0.2% -$1.96K 0.79% 29
2024
Q3
$710K Sell
572,632
-23,855
-4% -$30.1K 0.65% 34
2024
Q2
$799K Sell
596,487
-24,900
-4% -$36.7K 0.77% 30
2024
Q1
$845K Buy
621,387
+7,507
+1% +$16K 0.83% 30
2023
Q4
$1.61M Buy
+613,880
New +$1.49M 1.53% 15

Other funds holding APYX

Silverberg Bernstein Capital Management's APYX Position: Q3 2026 in Review

Silverberg Bernstein Capital Management reduced its Apyx Medical (APYX) stake by 1.7% in Q3 2026, selling an estimated $60.8K and leaving 1,022,239 shares worth $2.5M. The position accounts for 1.18% of the portfolio, ranked #21.

Silverberg Bernstein Capital Management first reported a position in APYX in Q4 2023 and has held it in 12 quarters since. The position peaked at $4.67M in Q2 2026. 69 funds tracked by Wall St. Rank hold APYX as of Q3 2026.

  • Silverberg Bernstein Capital Management held 1,022,239 shares of Apyx Medical worth $2.5M as of Q3 2026.
  • Silverberg Bernstein Capital Management sold 17,402 Apyx Medical shares in Q3 2026, an estimated $60.8K.
  • Apyx Medical made up 1.18% of Silverberg Bernstein Capital Management's portfolio in Q3 2026, its #21 holding.
  • Silverberg Bernstein Capital Management first reported a position in Apyx Medical in Q4 2023 and has held it in 12 quarters since.
  • Silverberg Bernstein Capital Management's Apyx Medical position peaked at $4.67M in Q2 2026.
  • 69 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.